nach oben

Erschienen in:

01.03.2011

Effect of Calcium and the Calcimimetic AMG 641 on Matrix-Gla Protein in Vascular Smooth Muscle Cells

verfasst von: Francisco J. Mendoza, Julio Martinez-Moreno, Yolanda Almaden, Maria E. Rodriguez-Ortiz, Ignacio Lopez, Jose Carlos Estepa, Charles Henley, Mariano Rodriguez, Escolastico Aguilera-Tejero

Erschienen in: Calcified Tissue International | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Vascular calcification (VC) is frequently observed in patients with chronic renal failure and appears to be an active process involving transdifferentiation of vascular smooth muscle cells (VSMCs) to osteoblast-like cells. Reports of VC prevention in uremic rodents by calcimimetics coupled with identification of the calcium-sensing receptor (CaSR) in VSMCs led us to hypothesize that CaSR activation in arterial cells and VSMCs may elicit expression of an endogenous inhibitor of VC. Toward this end, we determined the effects of calcium and the calcimimetic AMG 641 on arterial wall and isolated VSMC expression of matrix-Gla protein (MGP). Bovine VSMCs were incubated with increasing calcium chloride or AMG 641 concentrations, while in vivo experiments were carried out on healthy and uremic rats. Both AMG 641 and hypercalcemia induced MGP expression in the arterial wall in healthy and uremic rats. The results obtained in vitro supported those from in vivo experiments. In conclusion, selective CaSR activation, either by extracellular calcium or AMG 641, increased MGP expression in vivo in the arterial wall and in vitro in bovine VSMCs. This local upregulation of MGP expression provides one potential mechanism by which calcimimetics prevent VC.

Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161–1170PubMedCrossRef

Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRef

Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68:429–436PubMedCrossRef

Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRef

Chen NX, Moe SM (2004) Vascular calcification in chronic kidney disease. Semin Nephrol 24:61–68PubMedCrossRef

Chen NX, Moe SM (2006) Uremic vascular calcification. J Investig Med 54:380–384PubMedCrossRef

Steitz SA, Speer MY, Curing G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli GM (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89:1147–1154PubMedCrossRef

Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO₄, Ca × PO₄ product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMed

London GM, Drueke TB (1997) Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51:1678–1695PubMedCrossRef

10.

Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D (2006) Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 79:431–442PubMedCrossRef

11.

Moe SM, Reslerova M, Ketteler M, O’Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295–2304PubMedCrossRef

12.

Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 386:78–81PubMedCrossRef

13.

Price P, Otsuka A, Poser J, Kristaponis J, Raman N (1976) Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 73:1447–1451PubMedCrossRef

14.

Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL (1998) Calcification of human vascular cells in vitro is correlated with high levels of matrix gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 18:379–388PubMed

15.

Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmons M, Weissberg PL (2000) Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol 89(Suppl 2):63–68PubMedCrossRef

16.

Spronk HMH, Soute BAM, Schurgers LJ, Cleutjens JPM, Thijssen HHW, De Mey JGR, Vermeer C (2001) Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 289:485–490PubMedCrossRef

17.

Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, Gardiner RM, Chung E (1999) Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 21:142–144PubMedCrossRef

18.

Price PA, Faus SA, Williamson MK (1998) Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18:1400–1407PubMed

19.

Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, Massy ZA (2009) The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE^−/−) mice. Atherosclerosis 205:55–62PubMedCrossRef

20.

Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M (2006) Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17:795–804PubMedCrossRef

21.

De Francisco AL, Izquierdo M, Cunningham J, Piñera C, Palomar R, Fresnedo GF, Amado JA, Unzueta MG, Arias M (2008) Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23:2895–2901PubMedCrossRef

22.

Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M (2008) The effect of calcitriol, paricalcitol and calcimimetic AMG 641 on extraosseous calcifications in uremic rats. Kidney Int 73:300–307PubMedCrossRef

23.

Garfia B, Cañadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M (2003) Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13:2945–2952CrossRef

24.

Price PA, Faus SA, Williamson MK (2000) Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20:317–327PubMed

25.

Chomczynski P, Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1:581–585PubMedCrossRef

26.

Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E (2006) Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 21:484–490PubMedCrossRef

27.

Jono S, Nishizawa Y, Shioi A, Morii H (1998) 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98:1302–1306PubMed

28.

Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL (1994) High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393–2402PubMedCrossRef

29.

Mori K, Shioi A, Jono S, Nishizawa Y, Morii H (1998) Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 433:19–22PubMedCrossRef

30.

Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM (2000) Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 277:736–740PubMedCrossRef

31.

Nakatani S, Mano H, Ryanghyok IM, Shimizu J, Wada M (2006) Excess magnesium inhibits excess calcium-induced matrix-mineralization and production of matrix gla protein (MGP) by ATDC5 cells. Biochem Biophys Res Commun 348:1157–1162PubMedCrossRef

32.

Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM (2001) Transcriptional regulation of matrix gla protein. Z Kardiol 3:38–42

33.

Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D (2007) Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 293:F946–F955PubMedCrossRef

34.

Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield AE (2009) Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81:260–268PubMedCrossRef

35.

Molostvov G, Fletcher S, Bland R, Zehnder D (2008) Extracellular calcium-sensing receptor mediated signalling is involved in human vascular smooth muscle cell proliferation and apoptosis. Cell Physiol Biochem 22:413–422PubMedCrossRef

36.

Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S, Tfelt-Hansen J (2006) Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 348:1215–1223PubMedCrossRef

37.

Suttamanatwong S, Jensen ED, Schilling J, Franceschi RT, Carlson AE, Mansky KC, Gopalakrishnan R (2009) Sp proteins and Runx2 mediate regulation of matrix Gla protein (MGP) expression by parathyroid hormone. J Cell Biochem 107:284–292PubMedCrossRef

38.

Zebboudj AF, Shin V, Boström K (2003) Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 90:756–765PubMedCrossRef

39.

Koos R, Krueger T, Westenfeld R, Kühl HP, Brandenburg V, Mahnken AH, Stanzel S, Vermeer C, Cranenburg EC, Floege J, Kelm M, Schurgers LJ (2009) Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 101:706–713PubMed

40.

Schurgers LJ, Cranenburg ECM, Vermeer C (2008) Matrix-Gla protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100:593–603PubMed

Titel: Effect of Calcium and the Calcimimetic AMG 641 on Matrix-Gla Protein in Vascular Smooth Muscle Cells
verfasst von: Francisco J. Mendoza
Julio Martinez-Moreno
Yolanda Almaden
Maria E. Rodriguez-Ortiz
Ignacio Lopez
Jose Carlos Estepa
Charles Henley
Mariano Rodriguez
Escolastico Aguilera-Tejero
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 3/2011
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-010-9442-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Calcium Plus Vitamin D Supplementation Has Limited Effects on Femoral Geometric Strength in Older Postmenopausal Women: The Women’s Health Initiative

Interplay Between Serum Osteocalcin and Insulin Sensitivity in Primary Hyperparathyroidism

Increased Fracture Risk in Normocalcemic Postmenopausal Women with High Parathyroid Hormone Levels: A 16-Year Follow-Up Study

Steady and Oscillatory Fluid Flows Produce a Similar Osteogenic Phenotype

Role of Melastatin Transient Receptor Potential 7 Channels in the Osteoblastic Differentiation of Murine MC3T3 Cells